Bonnevie Pharma Profile
Key Indicators
- Authorised Capital ₹ 0.30 M
- Paid Up Capital ₹ 0.10 M
- Company Age 16 Year, 7 Months
- Last Filing with ROC 31 Mar 2024
- Open Charges ₹ 2.40 M
- Revenue Growth 4.52%
- Profit Growth -25.42%
- Ebitda 81.24%
- Net Worth 22.20%
- Total Assets -27.35%
About Bonnevie Pharma
Bonnevie Pharma Private Limited (BPPL) is a Private Limited Indian Non-Government Company incorporated in India on 14 July 2008 and has a history of 16 years and seven months. Its registered office is in Mumbai, Maharashtra, India.
The Company is engaged in the Pharma Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2024. It's a company limited by shares with an authorized capital of Rs 0.30 M and a paid-up capital of Rs 0.10 M.
The company currently has active open charges totaling ₹2.40 M.
Neha Dadhia and Veer Dadhia serve as directors at the Company.
Company Details
- Location
Mumbai, Maharashtra, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media -
Corporate Identity Details
- CIN/LLPIN
U24239MH2008PTC184631
- Company No.
184631
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
14 Jul 2008
- Date of AGM
30 Sep 2024
- Date of Balance Sheet
31 Mar 2024
- Listing Status
Unlisted
- ROC Code
Roc Mumbai
Industry
Who are the key members and board of directors at Bonnevie Pharma?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
| Neha Dadhia | Director | 19-Nov-2022 | Current |
Veer Dadhia  | Director | 14-Jul-2008 | Current |
Financial Performance of Bonnevie Pharma.
Bonnevie Pharma Private Limited, for the financial year ended 2016, experienced modest growth in revenue, with a 4.52% increase. The company also saw a substantial fall in profitability, with a 25.42% decrease in profit. The company's net worth Soared by an impressive increase of 22.2%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Bonnevie Pharma?
In 2017, Bonnevie Pharma had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Health Generics Lifescience Private LimitedVeer Dadhia is a mutual person
- Synthiko Exports Private Limited
Veer Dadhia is a mutual person
Charges (Loans)
₹2.40 M
₹0
Charges Breakdown by Lending Institutions
- Others : 0.24 Cr
Latest Charge Details
| Date | Lender | Amount | Status |
|---|---|---|---|
| 28 Sep 2015 | Others | ₹2.40 M | Open |
How Many Employees Work at Bonnevie Pharma?
Unlock and access historical data on people associated with Bonnevie Pharma, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Bonnevie Pharma, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Bonnevie Pharma's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.
